Portola Valley, CA – According to filings with the U.S. Securities and Exchange Commission, Angarus Therapeutics is raising $9,745,976.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Nigel Ray played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Angarus Therapeutics
Cancer is one of the leading causes of death worldwide. Although there are traditional treatments such as chemotherapy, surgery, and radiation therapy, these have demonstrated very limited efficacy, especially for patients with late-stage disease. Based in the San Francisco Bay Area, Angarus Therapeutics, Inc. responds to the urgent need to develop innovative immuno-oncology therapies. Cancer cells evolve to suppress both innate and adaptive responses by overexpressing immune checkpoints. Checkpoint blockers that unleash adaptive immune responses are achieving cancer-free long-term survival in some metastatic melanoma patients. However, most other cancer types suppress initial innate immune detection and therefore do not respond to adaptive checkpoint blockers. The scientists at Angarus are developing checkpoint blockers on the innate immunity STING pathway. Our preclinical data demonstrate that a combination of checkpoint blockers, both innate and adaptive, leads to long term survival. We plan to develop treatments that benefit patients with a wide-range of cancer types.

To learn more about Angarus Therapeutics, visit http://www.angarustherapeutics.com/

Contact:
Nigel Ray, Chief Executive Officer
650-575-1702
https://www.linkedin.com/in/nigelray/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved